Prelude Therapeutics Analyst Ratings
Prelude Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 177.78% | Morgan Stanley | $10 → $10 | Reiterates | Equal-Weight → Equal-Weight |
| 08/04/2023 | 38.89% | Barclays | $7 → $5 | Maintains | Equal-Weight |
| 03/17/2023 | 372.22% | HC Wainwright & Co. | $15 → $17 | Maintains | Buy |
| 11/21/2022 | 66.67% | B of A Securities | → $6 | Downgrades | Neutral → Underperform |
| 11/17/2022 | 316.67% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
| 11/15/2022 | 177.78% | Morgan Stanley | $11 → $10 | Maintains | Equal-Weight |
| 09/09/2022 | 205.56% | Morgan Stanley | $19 → $11 | Downgrades | Overweight → Equal-Weight |
| 07/29/2022 | 150% | Jefferies | → $9 | Initiates Coverage On | → Buy |
| 05/12/2022 | 344.44% | HC Wainwright & Co. | $62 → $16 | Maintains | Buy |
| 03/17/2022 | 427.78% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 03/15/2022 | 177.78% | B of A Securities | $50 → $10 | Downgrades | Buy → Neutral |
| 02/28/2022 | 233.33% | Barclays | $20 → $12 | Downgrades | Overweight → Equal-Weight |
| 11/17/2021 | 455.56% | Barclays | $33 → $20 | Maintains | Overweight |
| 10/11/2021 | 872.22% | Morgan Stanley | $60 → $35 | Upgrades | Equal-Weight → Overweight |
| 10/08/2021 | 816.67% | Barclays | $80 → $33 | Maintains | Overweight |
| 07/27/2021 | 1566.67% | B of A Securities | → $60 | Upgrades | Neutral → Buy |
| 04/26/2021 | 1622.22% | HC Wainwright & Co. | → $62 | Initiates Coverage On | → Buy |
| 03/17/2021 | 1566.67% | Morgan Stanley | $47 → $60 | Maintains | Equal-Weight |
| 12/16/2020 | 1205.56% | Morgan Stanley | $38 → $47 | Maintains | Equal-Weight |
| 11/12/2020 | 955.56% | Morgan Stanley | $34 → $38 | Maintains | Equal-Weight |
| 10/20/2020 | 1011.11% | B of A Securities | → $40 | Initiates Coverage On | → Buy |
| 10/20/2020 | 927.78% | Goldman Sachs | → $37 | Initiates Coverage On | → Neutral |
| 10/20/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/04/2023 | 177.78% | 摩根士丹利 | $10→$10 | 重申 | 等重→等重 |
| 08/04/2023 | 38.89% | 巴克萊 | $7→$5 | 維護 | 等重 |
| 03/17/2023 | 372.22% | HC Wainwright公司 | $15→$17 | 維護 | 買 |
| 2022年11月21日 | 66.67% | B of A證券 | →$6 | 評級下調 | 中性→表現不佳 |
| 2022年11月17日 | 316.67% | HC Wainwright公司 | $16→$15 | 維護 | 買 |
| 2022年11月15日 | 177.78% | 摩根士丹利 | $11→$10 | 維護 | 等重 |
| 09/09/2022 | 205.56% | 摩根士丹利 | $19→$11 | 評級下調 | 超重→等重 |
| 07/29/2022 | 150% | 傑富瑞 | →$9 | 開始承保 | →購買 |
| 2022年05月12日 | 344.44% | HC Wainwright公司 | $62→$16 | 維護 | 買 |
| 03/17/2022 | 427.78% | 摩根士丹利 | $20→$19 | 維護 | 超重 |
| 03/15/2022 | 177.78% | B of A證券 | $50→$10 | 評級下調 | 購買→中性 |
| 02/28/2022 | 233.33% | 巴克萊 | $20→$12 | 評級下調 | 超重→等重 |
| 2021年11月17日 | 455.56% | 巴克萊 | $33→$20 | 維護 | 超重 |
| 10/11/2021 | 872.22% | 摩根士丹利 | $60→$35 | 升級 | 等重→超重 |
| 10/08/2021 | 816.67% | 巴克萊 | $80→$33 | 維護 | 超重 |
| 07/27/2021 | 1566.67% | B of A證券 | →$60 | 升級 | 中性→購買 |
| 04/26/2021 | 1622.22% | HC Wainwright公司 | →$62 | 開始承保 | →購買 |
| 03/17/2021 | 1566.67% | 摩根士丹利 | $47→$60 | 維護 | 等重 |
| 12/16/2020 | 1205.56% | 摩根士丹利 | $38→$47 | 維護 | 等重 |
| 2020年11月12日 | 955.56% | 摩根士丹利 | $34→$38 | 維護 | 等重 |
| 10/20/2020 | 1011.11% | B of A證券 | →$40 | 開始承保 | →購買 |
| 10/20/2020 | 927.78% | 高盛 | →$37 | 開始承保 | →中性 |
| 10/20/2020 | - | 摩根士丹利 | 開始承保 | →等重 |
What is the target price for Prelude Therapeutics (PRLD)?
Prelude Treeutics(PRLD)的目標價格是多少？
The latest price target for Prelude Therapeutics (NASDAQ: PRLD) was reported by Morgan Stanley on August 4, 2023. The analyst firm set a price target for $10.00 expecting PRLD to rise to within 12 months (a possible 177.78% upside). 7 analyst firms have reported ratings in the last year.
摩根士丹利於2023年8月4日報道了Prelude Treateutics(納斯達克：PRLD)的最新目標價。這家分析公司將目標價定為10美元，預計PRLD將在12個月內上漲(可能上漲177.78%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Prelude Therapeutics (PRLD)?
Prelude Treeutics(PRLD)的最新分析師評級是什麼？
The latest analyst rating for Prelude Therapeutics (NASDAQ: PRLD) was provided by Morgan Stanley, and Prelude Therapeutics reiterated their equal-weight rating.
普瑞德治療公司(納斯達克代碼：PRLD)的最新分析師評級由摩根士丹利提供，普瑞魯治療公司重申其同等權重的評級。
When is the next analyst rating going to be posted or updated for Prelude Therapeutics (PRLD)?
Prelude Treeutics(PRLD)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prelude Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prelude Therapeutics was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Prelude Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Prelude治療公司的最後一次評級是在2023年8月4日提交的，所以你應該預計下一次評級將在2024年8月4日左右的某個時候提供。
Is the Analyst Rating Prelude Therapeutics (PRLD) correct?
分析師對Prelude Treeutics(PRLD)的評級正確嗎？
While ratings are subjective and will change, the latest Prelude Therapeutics (PRLD) rating was a reiterated with a price target of $10.00 to $10.00. The current price Prelude Therapeutics (PRLD) is trading at is $3.60, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Prelude Treeutics(PRLD)評級被重申，目標價在10.00美元至10.00美元之間。Prelude Treateutics(PRLD)目前的交易價格為3.60美元，超出了分析師的預測範圍。